首发精神分裂症药物的选择及疗效比较  

Drug selection and comparison of therapeutic effects on first-episode schizophrenia

作　　者：李红英[1] 王瑞文[1] 文胜慧 黄俊强[1] 

机构地区：[1]四川省复员退伍军人医院,四川崇州611236 [2]成都市第四人民医院

出　　处：《中国卫生工程学》2013年第3期250-252,共3页Chinese Journal of Public Health Engineering

摘　　要：目的比较临床常用首发精神分裂症药物的药效、副反应。方法选取我院及成都市第四人民医院2011年8月至2012年10月门诊及住院的首次发病精神病患者91例,随机分为奥氮平组(30例)、利培酮组(31例)和帕利哌酮组(30例),治疗8 w后对疗效、不良反应情况进行统计分析。结果 3组药物均能有效治疗首发精神分裂症,治疗前后相关指标比较差异均有统计学意义(P<0.01),3组之间疗效差异无统计学意义(P>0.05);奥氮平组锥体外系反应较少;帕利哌酮组对肝脏的损伤较少;利培酮组不易导致体重增加。结论临床应针对不同患者情况选择首发精神分裂症药物。Objective To compare the efficacy and side effects of clinic anti - schizophrenia drug. Methods Ninety - one first- episode schizophrenia patients were selected in outpatient hospital from August 2011 to October 2012, and randomly divided into the olanzapine group （30 cases） , risperidone group （ 30 cases） and palley risperidone （ 31 cases） and treated for 8 weeks, then the data were collected for statistical analysis. Results The drugs in the three groups all had a significant difference comparing relative indexes before and after treatment （ P 〈 0. O1 ）, efficacy had no difference among the three groups （ P 〉 0.05 ）. The olanzapine had a lighter extrapyramidal reactions, the palley risperidone had a lighter liver injury, the risperidone was hard to induce body weight increase. Conclusion Choice of anti - schizophrenia drugs should depend on different patients.

关 键 词：首发精神分裂症 奥氮平 利培酮 帕利哌酮 

分 类 号：R749[医药卫生—神经病学与精神病学]